Cargando…

Implementation of Ticagrelor Reduced Mortality in Routine Clinical Care: Evidence From a Natural Experiment Including 109 995 Patients With Myocardial Infarction in Sweden

BACKGROUND: Effectiveness estimates from observational studies on ticagrelor use in routine clinical care are conflicting, with some contrary to the results of the pivotal randomized controlled trial of ticagrelor in acute coronary syndrome. The aim of this study was to estimate the effect of implem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johannesen, Kasper, Siverskog, Jonathan, Henriksson, Martin, Janzon, Magnus, Lindahl, Bertil, Grönqvist, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111469/ https://www.ncbi.nlm.nih.gov/pubmed/36870964 http://dx.doi.org/10.1161/JAHA.122.027384

Ejemplares similares

Correction to: Implementation of Ticagrelor Reduced Mortality in Routine Clinical Care: Evidence From a Natural Experiment Including 109 995 Patients With Myocardial Infarction in Sweden
Publicado: (2023)

Subcategorizing the Expected Value of Perfect Implementation to Identify When and Where to Invest in Implementation Initiatives
por: Johannesen, Kasper, et al.
Publicado: (2020)

Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk
por: Tjerkaski, Jonathan, et al.
Publicado: (2023)

Estimating the marginal cost of a life year in Sweden’s public healthcare sector
por: Siverskog, Jonathan, et al.
Publicado: (2019)

Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients – A real life cohort study of two treatment strategies()
por: Alfredsson, Joakim, et al.
Publicado: (2020)

The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction
por: Henriksson, Robin, et al.
Publicado: (2019)

Effects of Ticagrelor on Myocardial Infarct Size
por: Hahn, Joo-Yong
Publicado: (2017)

Increase in ticagrelor use over time is associated with lower rates of ischemic stroke following myocardial infarction
por: Henriksson, Robin, et al.
Publicado: (2019)

Will Ticagrelor Help Post-Myocardial Infarction ‘Healing’?
por: Park, Kyung Woo
Publicado: (2019)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
por: Volney, Candice, et al.
Publicado: (2019)

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy
por: Janzon, M, et al.
Publicado: (2015)

Ticagrelor-Induced Torsades de Pointes following Myocardial Infarction
por: Bu, Seong Hyeon, et al.
Publicado: (2022)

Influence of health-related quality of life on time from symptom onset to hospital arrival and the risk of readmission in patients with myocardial infarction
por: Henriksson, Catrin, et al.
Publicado: (2014)

Treatment and Prognosis of Myocardial Infarction Outside Cardiology Departments
por: Gard, Anton, et al.
Publicado: (2020)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction
por: Scanavini-Filho, Marco Antonio, et al.
Publicado: (2022)

Ticagrelor versus clopidogrel for recurrent myocardial infarction: An outcomes-based agreement
por: Peasah, Samuel K., et al.
Publicado: (2023)

Impact of clinical diagnosis of myocardial infarction in patients with elevated cardiac troponin
por: Gard, Anton, et al.
Publicado: (2023)

Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf
por: Siverskog, Jonathan, et al.
Publicado: (2020)

Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis
por: Venetsanos, Dimitrios, et al.
Publicado: (2017)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor
por: Costa, Thiago Guarato Rodrigues, et al.
Publicado: (2022)

Strong development of research based on national quality registries in Sweden
por: Lysholm, Jack, et al.
Publicado: (2019)

Interphysician agreement on subclassification of myocardial infarction
por: Gard, Anton, et al.
Publicado: (2018)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006–2019: a registry-based cohort study
por: Leosdottir, Margret, et al.
Publicado: (2023)

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
por: Basra, Sukhdeep S., et al.
Publicado: (2018)

Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction
por: Akşit, Ercan, et al.
Publicado: (2020)

Safety and feasibility of low‐dose ticagrelor in patients with ST‐segment elevation myocardial infarction
por: Wang, Yanbo, et al.
Publicado: (2020)

Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
por: Samman, Karla N., et al.
Publicado: (2021)

Myocardial infarction after elective percutaneous coronary intervention—which cardiac troponin cut-off to use?
por: Eggers, Kai M, et al.
Publicado: (2021)

Using Ticagrelor to Prevent Recurrent Type 1 and Type 2 Myocardial Infarctions: Boon or Bane?
por: Bittl, John A.
Publicado: (2018)

Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Cassese, Salvatore, et al.
Publicado: (2020)

Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST‐Segment–Elevation Myocardial Infarctions
por: Schmucker, Johannes, et al.
Publicado: (2019)

Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost
por: Cao, Davide, et al.
Publicado: (2021)

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
por: Park, Keun-Ho, et al.
Publicado: (2021)

Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
por: Lee, Chih-Kuo, et al.
Publicado: (2021)

GH Secretory Dynamics and Responsiveness to SMS 201-995 Treatment in Acromegaly
por: Kim, Sung Woon, et al.
Publicado: (1988)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

995 Comparing the Clinical Presentation of Viral Causes of Pediatric Acute Gastroenteritis
por: Halasa, Natasha, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gped7e2ude57bl5e8r18l1ggi4